Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer
Avutometinib, defactinib, and to a larger extent their combinations, demonstrated promising in vitro and in vivo activity against EAC cell lines and xenografts. These preclinical data support the potential clinical evaluation of this combination in high-grade EAC patients.
Authors
- Cem Demirkiran (ORCID: https://orcid.org/0000-0002-7073-2819)
- Michelle Greenman (ORCID: https://orcid.org/0000-0003-1809-1468)
- Alessandro Davide Santin (ORCID: https://orcid.org/0000-0003-4724-9738)
- Stefania Bellone (ORCID: https://orcid.org/0000-0001-5909-5292)
- Yang Yang‐Hartwich (ORCID: https://orcid.org/0000-0002-0522-9053)
- Shuvro P. Nandi (ORCID: https://orcid.org/0000-0003-4855-4697)
- Sílvia Coma (ORCID: https://orcid.org/0000-0001-8109-2813)
- Jonathan A. Pachter (ORCID: https://orcid.org/0000-0002-0263-474X)
- Ludmil B. Alexandrov (ORCID: https://orcid.org/0000-0003-3596-4515)
- Tobias M.P. Hartwich (ORCID: https://orcid.org/0000-0002-2854-2894)
- Miranda Mansolf
- Blair McNamara
Institutions
- Yale University (US)
- University of California San Diego (US)
- Verastem (United States) (US)
Publication Details
- Journal
- Cancer Medicine
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1002/cam4.70210
- Citations
- 8
- Primary Topic
- Endometrial and Cervical Cancer Treatments
- Type
- article
- Field-Weighted Citation Impact
- 4.66
Funders
- Yale University
- Discovery To Cure
- Verastem Oncology
- National Institutes of Health
- National Cancer Institute